Compassionate use of <scp>long‐acting</scp> cabotegravir plus rilpivirine for people living with <scp>HIV</scp>‐1 in need of parenteral antiretroviral therapy

Ronald D’Amico, Annemiek de Ruiter(ViiV Healthcare (Spain)), Erika Van Landuyt(Janssen (Belgium)), Rodica Van Solingen‐Ristea(Janssen (Belgium)), Sherene Min(Unknown), Daniella Chilton(Guy's and St Thomas' NHS Foundation Trust), Bryan Baugh(Brigham and Women's Hospital), Sabine Allard(Vrije Universiteit Brussel), Caroline Foster(Imperial College Healthcare NHS Trust), Amy Cutrell(Triangle), Riya Moodley(ViiV Healthcare (United Kingdom)), Veerle Van Eygen(Janssen (Belgium)), Santiago Cenoz Gomis(ViiV Healthcare (Spain))
HIV Medicine
August 9, 2022
10.1111/hiv.13370
Cited by 46

Related Papers

Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen
|The Lancet|1996|631
Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006
|AIDS|2008|582
Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000–2011
|AIDS|2014|397
Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy
|AIDS|2002|359
Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1
|Annals of Internal Medicine|2014|262